Research Articles

Compiled for your convenience are articles on bone marrow failure research and treatment from the world’s major journals on hematology / oncology.

Article Title Original Publication Date Journal Bone Marrow Disease
Immunosuppressive therapy for pediatric aplastic anemia: a North American Pediatric Aplastic Anemia Consortium study Haematologica Aplastic Anemia
Immunosuppression and Growth Factors for Severe Aplastic Anemia: New Data for Old Questions Haematologica Aplastic Anemia
Immunomodulation With Pomalidomide at Early Lymphocyte Recovery After Induction Chemotherapy in Newly Diagnosed AML and High-Risk MDS Leukemia Acute Myeloid Leukemia (AML), Myelodysplastic Syndromes (MDS)
Imetelstat in patients with lower-risk myelodysplastic syndromes who have relapsed or are refractory to erythropoiesis-stimulating agents (IMerge): a multinational, randomised, double-blind, placebo-controlled, phase 3 trial Lancet Myelodysplastic Syndromes (MDS)
Imetelstat Achieves Meaningful and Durable Transfusion Independence in High Transfusion-Burden Patients With Lower-Risk Myelodysplastic Syndromes in a Phase II Study Journal of clinical oncology: official journal of the American Society Clinical Oncology Myelodysplastic Syndromes (MDS)
Imetelstat Achieves Meaningful and Durable Transfusion Independence in High Transfusion-Burden Patients With Lower-Risk Myelodysplastic Syndromes in a Phase II Study Journal of clinical oncology: official journal of the American Society Clinical Oncology Myelodysplastic Syndromes (MDS)
Imetelstat Achieves Meaningful and Durable Transfusion Independence in High Transfusion-Burden Patients With Lower-Risk Myelodysplastic Syndromes in a Phase II Study Journal of clinical oncology: official journal of the American Society Clinical Oncology Myelodysplastic Syndromes (MDS)
Idiopathic aplastic anemia vs hypocellular myelodysplastic syndrome Hematology. American Society of Hematology. Education Program Aplastic Anemia
Hypomethylating agents are associated with high rates of hematologic toxicity in patients with secondary myeloid neoplasms developing after acquired aplastic anemia Haematologica Aplastic Anemia
Hypomethylating agents are associated with high rates of hematologic toxicity in patients with secondary myeloid neoplasms developing after acquired aplastic anemia Haematologica Aplastic Anemia

Website Feedback

Please use this feedback form to report website issues only. For other issues concerning patients and families, please email help@aamds.org or use the Patient and Family Helpline here.

We Recommend

For Research